Russian regulatory system for clinical trials is consistent with international approaches
Clinical trials are the most important stage in the development of effective and safe medicinal products. Yu.N. Linkova, Candidate of Medical Sciences, Vice President for Clinical Research and Development at BIOCAD, shares her perspective on clinical trial regulation in the Russian Federation.
Saved in:
| Main Author: | Yu. N. Linkova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2023-12-01
|
| Series: | Регуляторные исследования и экспертиза лекарственных средств |
| Subjects: | |
| Online Access: | https://www.vedomostincesmp.ru/jour/article/view/592 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Approaches to clinical development of combination medicines in the Russian Federation and the Eurasian Economic Union in view of the requirements of the current legislation
by: A. V. Dobrovolskiy
Published: (2019-03-01) -
Conducting Pharmaceutical Inspections in the Russian Federation to Ensure Compliance with the EAEU GCP Requirements Is an Accepted Necessity
by: A. A. Trapkova
Published: (2023-06-01) -
Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption
by: Claudia Eder, et al.
Published: (2019-01-01) -
Marketing Authorisation Based on Incomplete Clinical Data: International Experience and Prospects
by: D. V. Goryachev, et al.
Published: (2020-09-01) -
Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China)
by: E. V. Melnikova, et al.
Published: (2021-10-01)